Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 12, 2023
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?
A Giordano, N U Lin, S M Tolaney, et al.
Cell and Tissue Research
|
March 1, 1987
Transport of membrane-bound macromolecules by M cells in follicle-associated epithelium of rabbit Peyer's patch
M R Neutra, T L Phillips, E L Mayer, et al.
ESMO Open
|
November 7, 2024
Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer
G Nader-Marta, A G Waks, S M Tolaney, et al.
The Journal of Biological Chemistry
|
September 20, 1996
Purification and characterization of the vaccinia virus deoxyuridine triphosphatase expressed in Escherichia coli
N A Roseman, R K Evans, E L Mayer, et al.
Breast Cancer Research and Treatment
|
March 19, 2009
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
E L Mayer, A H Partridge, L N Harris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 26, 2010
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
E L Mayer, S Dhakil, T Patel, et al.
Circulation
|
December 1, 1996
Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
K Robinson, A Gupta, V Dennis, et al.
Circulation
|
November 15, 1995
Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease
K Robinson, E L Mayer, D P Miller, et al.
Breast Cancer Research and Treatment
|
May 7, 2013
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
N U Lin, D S Seah, R Gelman, et al.
ESMO Open
|
June 4, 2024
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer
A Grinshpun, S Ren, N Graham, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 12, 2023
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?
A Giordano, N U Lin, S M Tolaney, et al.
Cell and Tissue Research
|
March 1, 1987
Transport of membrane-bound macromolecules by M cells in follicle-associated epithelium of rabbit Peyer's patch
M R Neutra, T L Phillips, E L Mayer, et al.
ESMO Open
|
November 7, 2024
Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer
G Nader-Marta, A G Waks, S M Tolaney, et al.
The Journal of Biological Chemistry
|
September 20, 1996
Purification and characterization of the vaccinia virus deoxyuridine triphosphatase expressed in Escherichia coli
N A Roseman, R K Evans, E L Mayer, et al.
Breast Cancer Research and Treatment
|
March 19, 2009
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
E L Mayer, A H Partridge, L N Harris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 26, 2010
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
E L Mayer, S Dhakil, T Patel, et al.
Circulation
|
December 1, 1996
Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
K Robinson, A Gupta, V Dennis, et al.
Circulation
|
November 15, 1995
Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease
K Robinson, E L Mayer, D P Miller, et al.
Breast Cancer Research and Treatment
|
May 7, 2013
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
N U Lin, D S Seah, R Gelman, et al.
ESMO Open
|
June 4, 2024
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer
A Grinshpun, S Ren, N Graham, et al.
Page
of 4